Gilead Sciences reports strong Q2 2025 results, raises full-year guidance, and sees stock surge to highest level since 2015 amid optimism about its strategy and pipeline.
Gilead Sciences reports strong Q2 2025 results, raises full-year guidance, and sees stock surge to highest level since 2015 amid optimism about its strategy and pipeline.